Loading insider details...
Beta
Latest Form 4 (Jul 17, 2026): Disposition to Issuer of 8,299,225 NUVL shares, $1.03B.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Jul 17, 2026 | Nuvalent, Inc. (NUVL) | Disposition to Issuer | 8,299,225 | $1.03B |
| Jun 18, 2026 | Nuvalent, Inc. (NUVL) | Grant/Award | 3,444 | n/a |
| Jun 12, 2026 | Parabilis Medicines, Inc. (PBLS) | Conversion | 122,990 | n/a |
| May 21, 2026 | Larimar Therapeutics, Inc. (LRMR) | Grant/Award | 55,150 | n/a |
| Mar 3, 2026 | Larimar Therapeutics, Inc. (LRMR) | Purchase | 1,084,010 | $5.42M |
| Nov 25, 2025 | Nuvalent, Inc. (NUVL) | Sale | 371,287 | $35.44M |
| Aug 4, 2025 | Larimar Therapeutics, Inc. (LRMR) | Purchase | 3,387,529 | $10.84M |
| Jul 1, 2025 | ARS Pharmaceuticals, Inc. (SPRY) | Sale | 370,075 | $6.83M |
| Jun 21, 2025 | Nuvalent, Inc. (NUVL) | Grant/Award | 2,647 | n/a |
| May 15, 2025 | Larimar Therapeutics, Inc. (LRMR) | Grant/Award | 19,000 | n/a |